Innoviva, Inc. (Nasdaq:INVA)

Health Care/Life Sciences • Pharmaceuticals

CIK 1080014

Company

Innoviva, Inc. is engaged in the development, commercialization, and financial management of biopharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate, and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.

Address
1350 Old Bayshore Highway
Suite 400
Burlingame, California 94010

Employees
112

Stock Info

Close
$17.61

Day Range
17.43 - 17.74

52 Week Range
14.33 - 21.28

Average volume
578.84K

Short Interest
8.98M (02/14/25)

% of Float Shorted
14.48%

Market Cap
$1.1B

Revenue
$324.26M

Net Income
$179.72M

2020 Sales Growth
N/A

Rev. per Employee
N/A

P/E Ratio
84.18

EPS
$0.21

Yield
N/A

Dividend
N/A

Ex-Dividend Date
N/A

Key Executives

Board Of Directors

Director
Odysseas Demosthenes Kostas

Independent Director
Derek A. Small

Independent Director
Sapna R. Srivastava

Independent Director
Jules Haimovitz

Lead Independent Director
Sarah J. Schlesinger

SEC filings

Date	Form	Event
22 Nov, 2024	4
14 Nov, 2024	SC 13D/A
6 Nov, 2024	10-Q
6 Nov, 2024	8-K
1 Nov, 2024	UPLOAD
26 Sep, 2024	CORRESP
13 Sep, 2024	UPLOAD
22 Aug, 2024	4
31 Jul, 2024	10-Q
31 Jul, 2024	8-K
20 Jun, 2024	8-K
20 Jun, 2024	4
20 Jun, 2024	4
20 Jun, 2024	4
20 Jun, 2024	4
20 Jun, 2024	4
20 Jun, 2024	4
21 May, 2024	4
21 May, 2024	4
13 May, 2024	SC 13G
13 May, 2024	8-K
9 May, 2024	ARS
8 May, 2024	SC 13D
8 May, 2024	10-Q
8 May, 2024	8-K
1 May, 2024	3
30 Apr, 2024	8-K
29 Apr, 2024	DEF 14A
29 Apr, 2024	DEFA14A
22 Mar, 2024	10-K/A
7 Mar, 2024	4
7 Mar, 2024	4
7 Mar, 2024	4
7 Mar, 2024	4
5 Mar, 2024	10-K/A
4 Mar, 2024	SC 13D/A
29 Feb, 2024	8-K
29 Feb, 2024	10-K
22 Feb, 2024	4
22 Feb, 2024	4
14 Feb, 2024	SC 13G/A
13 Feb, 2024	SC 13G/A
13 Feb, 2024	SC 13G/A
9 Feb, 2024	SC 13G
22 Jan, 2024	4
22 Jan, 2024	SC 13G/A
10 Jan, 2024	3
22 Nov, 2023	4
17 Nov, 2023	4
13 Nov, 2023	S-8
6 Nov, 2023	8-K
1 Nov, 2023	8-K
1 Nov, 2023	10-Q
31 Aug, 2023	4
31 Aug, 2023	4
31 Aug, 2023	3
25 Aug, 2023	8-K
7 Aug, 2023	8-K
2 Aug, 2023	4
2 Aug, 2023	8-K
2 Aug, 2023	10-Q
2 Aug, 2023	3
11 Jul, 2023	SC 13D/A
11 Jul, 2023	8-K	CEO Change
7 Jun, 2023	4
30 May, 2023	4
24 May, 2023	4
24 May, 2023	4
24 May, 2023	4
24 May, 2023	4
24 May, 2023	4
24 May, 2023	8-K
24 May, 2023	8-K
24 May, 2023	4
23 May, 2023	4
19 May, 2023	4
19 May, 2023	4/A
17 May, 2023	DEFA14A
15 May, 2023	4
15 May, 2023	SC 13D/A
15 May, 2023	3
9 May, 2023	10-Q
9 May, 2023	8-K
1 May, 2023	8-K
1 May, 2023	DEFA14A
28 Apr, 2023	DEF 14A
28 Apr, 2023	ARS
17 Apr, 2023	4
20 Mar, 2023	10-K/A
14 Mar, 2023	4
28 Feb, 2023	10-K
28 Feb, 2023	8-K
22 Feb, 2023	4
14 Feb, 2023	SC 13G
13 Feb, 2023	SC 13G/A
10 Feb, 2023	SC 13G/A
9 Feb, 2023	SC 13G/A
2 Feb, 2023	SC 13G/A
26 Jan, 2023	SC 13G/A
20 Jan, 2023	SC 13G
12 Jan, 2023	4
10 Jan, 2023	SC 13D/A
6 Jan, 2023	3
4 Jan, 2023	8-K
22 Nov, 2022	4
9 Nov, 2022	10-Q
9 Nov, 2022	8-K
28 Oct, 2022	8-K/A
14 Sep, 2022	8-K
26 Aug, 2022	3
23 Aug, 2022	8-K
22 Aug, 2022	8-K
22 Aug, 2022	SC TO-T/A
22 Aug, 2022	4
16 Aug, 2022	SC TO-T/A
27 Jul, 2022	8-K
27 Jul, 2022	10-Q
25 Jul, 2022	SC TO-T
20 Jul, 2022	8-K
13 Jul, 2022	8-K
13 Jul, 2022	4
11 Jul, 2022	425
11 Jul, 2022	SC 13G/A
11 Jul, 2022	SC 13D/A
11 Jul, 2022	8-K
11 Jul, 2022	8-K
11 Jul, 2022	SC TO-C
8 Jul, 2022	SC 13E3/A
8 Jul, 2022	SC TO-T/A
17 Jun, 2022	SC TO-T/A
17 Jun, 2022	CORRESP
17 Jun, 2022	SC 13E3/A
7 Jun, 2022	SC TO-T
7 Jun, 2022	SC 13E3
24 May, 2022	SC TO-C
24 May, 2022	8-K
24 May, 2022	SC TO-C
24 May, 2022	SC 13D/A
23 May, 2022	4
5 May, 2022	10-Q
4 May, 2022	4
4 May, 2022	8-K/A
2 May, 2022	8-K
29 Apr, 2022	8-K
28 Apr, 2022	8-K
27 Apr, 2022	4
27 Apr, 2022	4
27 Apr, 2022	4
27 Apr, 2022	4
27 Apr, 2022	4
27 Apr, 2022	4
7 Apr, 2022	8-K
1 Apr, 2022	8-K
1 Apr, 2022	4
1 Apr, 2022	SC 13D/A
25 Mar, 2022	8-K
25 Mar, 2022	DEF 14A
21 Mar, 2022	8-K
17 Mar, 2022	10-K/A
15 Mar, 2022	SC 13D/A
8 Mar, 2022	8-K
2 Mar, 2022	4
28 Feb, 2022	10-K
23 Feb, 2022	4
22 Feb, 2022	SC 13D/A
22 Feb, 2022	4
11 Feb, 2022	4
11 Feb, 2022	SC 13D/A
11 Feb, 2022	SC 13G/A
10 Feb, 2022	SC 13G/A
9 Feb, 2022	8-K
2 Feb, 2022	SC 13D/A
1 Feb, 2022	SC 13G
28 Jan, 2022	SC 13G/A
13 Dec, 2021	8-K
22 Nov, 2021	4
1 Nov, 2021	4
1 Nov, 2021	SC 13D/A
27 Oct, 2021	8-K
27 Oct, 2021	10-Q
24 Aug, 2021	4/A
23 Aug, 2021	4
29 Jul, 2021	10-Q
28 Jul, 2021	8-K
14 Jun, 2021	SC 13D/A
11 Jun, 2021	4
7 Jun, 2021	SC 13G/A
26 May, 2021	8-K
25 May, 2021	4
25 May, 2021	SC 13D/A
25 May, 2021	SC 13D/A
25 May, 2021	4
24 May, 2021	4
24 May, 2021	4
20 May, 2021	4
20 May, 2021	4
20 May, 2021	4
20 May, 2021	4
20 May, 2021	4
20 May, 2021	4
20 May, 2021	4
20 May, 2021	8-K
20 May, 2021	8-K
5 May, 2021	DEFA14A
3 May, 2021	SC 13D/A
28 Apr, 2021	8-K
28 Apr, 2021	10-Q
5 Apr, 2021	SC 13D/A
2 Apr, 2021	DEF 14A
30 Mar, 2021	4
30 Mar, 2021	4
24 Mar, 2021	4
17 Mar, 2021	4
17 Mar, 2021	SC 13D/A
16 Mar, 2021	3
10 Mar, 2021	8-K
25 Feb, 2021	10-K
22 Feb, 2021	4
12 Feb, 2021	SC 13D/A
11 Feb, 2021	SC 13G/A
10 Feb, 2021	SC 13G/A
3 Feb, 2021	8-K
28 Jan, 2021	4
27 Jan, 2021	SC 13G/A
27 Jan, 2021	SC 13D/A

Last update:2025-03-06 12:24:57.171124

Sign Up to Subscribe

Interested in special situations?

Join Tickerverse

customize event filters
create watchlists, bookmarks
get email notifications for the latest special situations
browse and analyze public companies, executives and SEC filings

Tickerverse is a great way to find investment opportunities in corporate actions.

By signing up you agree to our Terms of Service and Privacy Policy.